|
시장보고서
상품코드
2054404
고지혈증 치료제 시장 : 약제 클래스별 및 지역별Antihyperlipidemic Drugs Market, By Drug Class, and By Geography |
||||||
고지혈증 치료제 시장은 2026년에 169억 3,000만 달러로 추정되고 있으며, 2033년까지 284억 6,000만 달러에 이를 것으로 예상되고 있습니다. 2026-2033년 CAGR 7.7%로 성장할 전망입니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도 : | 2025년 | 시장 규모 : 2026년 | 169억 3,000만 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 예측 기간 CAGR : 2026-2033년 | 7.70% | 시장 규모 예측 : 2033년 | 284억 6,000만 달러 |
고지혈증이란 혈액 내 콜레스테롤이나 중성지방 등의 지질 수치가 상승하는 다양한 유전성 및 후천성 질환을 통칭하는 용어입니다. 이로 인해 전 세계 사망 원인 1위인 심장병이나 뇌졸중의 위험이 높아집니다. 이는 매우 흔한 질환이기 때문에 고지혈증 및 심혈관 질환의 위험을 줄이는 데 도움이 되는 항고지혈증제에 대한 수요가 전 세계적으로 증가하고 있습니다.
시장 역학 :
고지혈증 유병률 증가, 앉아 있는 생활 습관의 급증, 고령 인구 증가, 고지혈증 치료제에 대한 수요 증가, 그리고 신약 출시가 전 세계 고지혈증 치료제 시장의 성장을 가속할 것으로 예상되는 주요 요인입니다.
예를 들어, 미국 뇌졸중 협회(American Stroke Association)에 따르면, 뇌졸중은 미국에서 5번째로 많은 사망 원인이자 장애의 주요 원인입니다. 미국에서는 매년 79만 5,000명 이상이 뇌졸중을 앓고 있습니다. 이 중 약 61만 명은 첫 뇌졸중이거나 새로 발병한 뇌졸중입니다.
또한, AHA 저널의 보고에 따르면, 유럽에서도 뇌졸중은 가장 흔한 사망 원인일 뿐만 아니라 성인의 장애를 유발하는 주요 원인이기도 합니다. '유럽 뇌졸중 행동 계획(SAP-E)'은 2030년까지 근거에 기반한 예방 조치 및 뇌졸중 의료 서비스 제공을 위한 목표를 설정하는 유럽 전역을 아우르는 프로젝트입니다.
본 조사의 주요 특징 :
- 본 조사는 다양한 부문의 잠재적 수익 기회를 파악하고, 이 시장의 매력적인 투자 제안 매트릭스를 설명하고 있습니다.
- 또한, 본 조사에서는 시장 성장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 그리고 주요 기업들이 채택하는 경쟁 전략에 관한 중요한 인사이트를 제공합니다.
- 본 조사에서는 기업 개요, 제품 포트폴리오, 주요 성과, 재무 실적, 전략 등의 지표를 바탕으로 전 세계 고지혈증 치료제 시장의 주요 기업 프로파일을 작성하고 있습니다.
- 본 보고서의 인사이트를 활용함으로써, 기업의 마케팅 담당자 및 경영진은 향후 제품 출시, 제품 업그레이드, 시장 확대 및 마케팅 전략에 관해 정보에 기반한 의사결정을 내릴 수 있게 됩니다.
- 본 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진출기업, 금융 애널리스트 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계의 고지혈증 치료제 시장 분석에 활용되는 다양한 전략 매트릭스를 통해 의사결정을 보다 수월하게 내릴 수 있을 것입니다.
목차
제1장 조사 목적 및 전제조건
제2장 시장 전망
제3장 시장 역학, 규제 및 동향 분석
제4장 세계의 고지혈증 치료제 시장 : 약제 클래스별(2021-2033년)
제5장 세계의 고지혈증 치료제 시장 : 지역별(2021-2033년)
제6장 경쟁 구도
제7장 섹션
AJY 26.06.17Antihyperlipidemic Drugs Market is estimated to be valued at USD 16.93 Bn in 2026 and is expected to reach USD 28.46 Bn by 2033, growing at a compound annual growth rate (CAGR) of 7.7% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 16.93 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 7.70% | 2033 Value Projection: | USD 28.46 Bn |
Hyperlipidemia is a term that encompasses various genetic and acquired disorders that describe an elevated lipid levels, such as cholesterol and triglycerides, in the blood, which in turn increases the risk of heart disease and stroke, the leading cause of death worldwide. It is a very common disorder, and thus, there is an increasing demand for antihyperlipidemic drugs across the world, as they help reduce the risk of hyperlipidemia and cardiovascular diseases.
Market Dynamics:
Increasing prevalence of hyperlipidemia, surge in sedentary lifestyle, growing geriatric population, increasing demand for antihyperlipidemic drugs, and introduction of novel drugs are major factors expected to augment the growth of the global antihyperlipidemic drugs market.
For instance, according to the American Stroke Association, stroke is the No. 5 cause of death and a leading cause of disability in the United States. Every year, more than 795,000 people in the U.S. have a stroke. About 610,000 of these are first or new strokes.
Moreover, according to the repost by AHA Journals, in Europe, stroke is the most common cause of death as well as a leading cause of adult disability. The Stroke Action Plan for Europe (SAP-E) is a pan-European project that sets targets for the implementation of an evidence-based preventive actions and stroke services until 2030.
Key features of the study:
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global antihyperlipidemic drugs market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include Sanofi S.A., Pfizer Inc., Mylan N.V, Amgen Inc., Abbvie Inc., Merck & Co., Inc., Dr. Reddy's Laboratories Ltd., Bristol-Myers Squibb Company, AstraZeneca plc, and Daiichi Sankyo Company, Limited, among others.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- The global antihyperlipidemic drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global antihyperlipidemic drugs market.
Detailed Segmentation:
- Global Antihyperlipidemic Drugs Market, By Drug Class (Revenue, USD Bn, 2021 - 2033)
- Statins
- Bile Acid Sequestrants
- Cholesterol Absorption Inhibitors
- Fibric Acid Derivatives
- PCSK9 Inhibitors
- Combination
- Others
- Regional Insights (Revenue, USD Bn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Company Profiles:
- Sanofi S.A.
- Pfizer Inc.
- Mylan N.V.
- Amgen Inc.
- Abbvie Inc.
- Merck & Co., Inc.
- Reddy's Laboratories Ltd.
- Bristol-Myers Squibb Company
- AstraZeneca plc
- Daiichi Sankyo Company, Limited, among others.
Table of Contents:
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Drug Class
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Increasing prevalence of hyperlipidemia worldwide
- High cost of treatment and lack of awareness
- Increasing demand for antihyperlipidemic drugs
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product launch/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
4. Global Antihyperlipidemic Drugs Market, By Drug Class, 2021 - 2033, (US$ Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Statins
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Bile Acid Sequestrants
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Cholesterol Absorption Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Fibric Acid Derivatives
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- PCSK9 Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Combination
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
5. Global Antihyperlipidemic Drugs Market, By Region, 2021 - 2033, (US$ Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033,(US$ Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033,(US$ Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033,(US$ Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033,(US$ Bn)
- China
- Japan
- India
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033,(US$ Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033,(US$ Bn)
- South Africa
- North Africa
- Central Africa
6. Competitive Landscape
- Sanofi S.A.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Mylan N.V.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Amgen Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Abbvie Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Merck & Co., Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Dr. Reddy's Laboratories Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bristol-Myers Squibb Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AstraZeneca plc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Daiichi Sankyo Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Analyst Views
7. Section
- Research Methodology
- About us
